These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10636116)

  • 41. [Primary ectopic intraosseous meningioma associated with multiple meningioma in a patient with central neurofibromatosis].
    Poptodorov G; Gabrovski S; Kamenova M; Nacheva M; Iordanov I; Shirov T; Petkov R; Dŭbov D
    Khirurgiia (Sofiia); 2006; (4-5):64-7. PubMed ID: 18843923
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neurofibromatosis type 2: molecular and clinical analyses in Argentine sporadic and familial cases.
    Ferrer M; Schulze A; Gonzalez S; Ferreiro V; Ciavarelli P; Otero J; Giliberto F; Basso A; Szijan I
    Neurosci Lett; 2010 Aug; 480(1):49-54. PubMed ID: 20553997
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multiple and familial meningiomas without evidence of neurofibromatosis.
    Memon MY
    Neurosurgery; 1980 Sep; 7(3):262-4. PubMed ID: 6782502
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Meningioma and schwannoma risk in adults in relation to family history of cancer.
    Hill DA; Linet MS; Black PM; Fine HA; Selker RG; Shapiro WR; Inskip PD
    Neuro Oncol; 2004 Oct; 6(4):274-80. PubMed ID: 15494094
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas.
    Gutmann DH; Donahoe J; Perry A; Lemke N; Gorse K; Kittiniyom K; Rempel SA; Gutierrez JA; Newsham IF
    Hum Mol Genet; 2000 Jun; 9(10):1495-500. PubMed ID: 10888600
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The molecular pathology of tumours of the ear and temporal bone.
    Irving RM
    J Laryngol Otol; 1998 Nov; 112(11):1011-8. PubMed ID: 10197136
    [No Abstract]   [Full Text] [Related]  

  • 47. Identification and characterization of genes differentially expressed in meningiomas.
    Murphy M; Pykett MJ; Harnish P; Zang KD; George DL
    Cell Growth Differ; 1993 Sep; 4(9):715-22. PubMed ID: 7694637
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Familial meningioma.
    McDowell JR
    Neurology; 1990 Feb; 40(2):312-4. PubMed ID: 2300254
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Familial meningiomas. Report of two cases.
    Ferrante L; Acqui M; Mastronardi L; Nucci F
    J Neurosurg Sci; 1987; 31(3):145-51. PubMed ID: 3329680
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Infratentorial meningioma in an 8-year-old child as first sign of neurofibromatosis type 2.
    Stettner GM; Rostasy KM; Ludwig HC; Merkler D; Fahsold R; Gärtner J
    Neuropediatrics; 2007 Feb; 38(1):29-31. PubMed ID: 17607601
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Meningiomas in five members of a family over two generations, in one member simultaneously with acoustic neurinomas.
    Delleman JW; De Jong JG; Bleeker GM
    Neurology; 1978 Jun; 28(6):567-70. PubMed ID: 418361
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Germline and somatic mutations in meningiomas.
    Smith MJ
    Cancer Genet; 2015 Apr; 208(4):107-14. PubMed ID: 25857641
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Unilateral vestibular schwannoma and meningiomas in a patient with PIK3CA-related segmental overgrowth: Co-occurrence of mosaicism for 2 rare disorders.
    Mills JR; Moyer AM; Kipp BR; Poplawski AB; Messiaen LM; Babovic-Vuksanovic D
    Clin Genet; 2018 Jan; 93(1):187-190. PubMed ID: 28737257
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular genetic investigation of the neurofibromatosis type 2 tumor suppressor gene in sporadic meningioma.
    Harada T; Irving RM; Xuereb JH; Barton DE; Hardy DG; Moffat DA; Maher ER
    J Neurosurg; 1996 May; 84(5):847-51. PubMed ID: 8622160
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas.
    Dickinson PJ; Surace EI; Cambell M; Higgins RJ; Leutenegger CM; Bollen AW; LeCouteur RA; Gutmann DH
    Vet Pathol; 2009 Sep; 46(5):884-92. PubMed ID: 19429976
    [TBL] [Abstract][Full Text] [Related]  

  • 56. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
    Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
    BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intracranial meningiomas and neurofibromatosis type 2.
    Gokce G; Ceylan OM; Mutlu FM; Altinsoy HI
    Acta Neurochir (Wien); 2014 Jun; 156(6):1103. PubMed ID: 24652317
    [No Abstract]   [Full Text] [Related]  

  • 58. Genetic/molecular alterations of meningiomas and the signaling pathways targeted.
    Domingues P; González-Tablas M; Otero Á; Pascual D; Ruiz L; Miranda D; Sousa P; Gonçalves JM; Lopes MC; Orfao A; Tabernero MD
    Oncotarget; 2015 May; 6(13):10671-88. PubMed ID: 25965831
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [NF2].
    Takeshima H; Ushio Y
    No To Shinkei; 1998 Jun; 50(6):529-37. PubMed ID: 9656248
    [No Abstract]   [Full Text] [Related]  

  • 60. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types.
    James MF; Stivison E; Beauchamp R; Han S; Li H; Wallace MR; Gusella JF; Stemmer-Rachamimov AO; Ramesh V
    Mol Cancer Res; 2012 May; 10(5):649-59. PubMed ID: 22426462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.